Knight Therapeutics Inc. (TSE:GUD - Get Free Report) insider Sime Armoyan sold 92,200 shares of Knight Therapeutics stock in a transaction on Monday, March 17th. The stock was sold at an average price of C$6.15, for a total transaction of C$567,030.00.
Sime Armoyan also recently made the following trade(s):
- On Thursday, March 13th, Sime Armoyan sold 1,100 shares of Knight Therapeutics stock. The shares were sold at an average price of C$6.10, for a total transaction of C$6,710.00.
- On Tuesday, March 4th, Sime Armoyan acquired 17,600 shares of Knight Therapeutics stock. The shares were acquired at an average price of C$5.48 per share, for a total transaction of C$96,488.48.
Knight Therapeutics Trading Up 0.3 %
Shares of TSE:GUD opened at C$6.19 on Wednesday. The company has a quick ratio of 1.79, a current ratio of 3.36 and a debt-to-equity ratio of 7.52. The company's 50-day moving average price is C$5.63 and its 200 day moving average price is C$5.56. The company has a market cap of C$626.12 million, a PE ratio of -20.67, a P/E/G ratio of -1,013.50 and a beta of 0.50. Knight Therapeutics Inc. has a fifty-two week low of C$5.09 and a fifty-two week high of C$6.25.
Analyst Ratings Changes
Separately, Research Capitl raised Knight Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday, March 11th. Two analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Strong Buy" and a consensus price target of C$7.08.
Read Our Latest Stock Analysis on Knight Therapeutics
About Knight Therapeutics
(
Get Free Report)
Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
